Publications by authors named "Cixin Steven He"

Background: Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-related quality-of-life (HRQOL) outcomes from the CLEAR study.

Methods: This open-label, randomised, phase 3 study was done across 200 hospitals and cancer centres in 20 countries.

View Article and Find Full Text PDF